Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by research analysts at TheStreet from a “c-” rating to a “d+” rating in a report issued on Monday, TheStreetRatingsTable reports.
Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. BidaskClub downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Oxford Immunotec Global presently has an average rating of “Hold” and an average price target of $18.00.
NASDAQ OXFD opened at $13.17 on Monday. The stock has a market capitalization of $353.82 million, a P/E ratio of 25.82 and a beta of 0.35. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average is $14.10. Oxford Immunotec Global has a fifty-two week low of $11.66 and a fifty-two week high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. The company had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. Oxford Immunotec Global’s quarterly revenue was up 26.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) earnings per share. Sell-side analysts anticipate that Oxford Immunotec Global will post -0.24 earnings per share for the current fiscal year.
In other news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $48,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.21% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC lifted its position in shares of Oxford Immunotec Global by 15.0% in the second quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock valued at $343,000 after acquiring an additional 3,255 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Oxford Immunotec Global in the first quarter worth about $1,185,000. Granite Investment Partners LLC purchased a new stake in shares of Oxford Immunotec Global in the first quarter worth about $1,174,000. FIL Ltd purchased a new stake in shares of Oxford Immunotec Global in the first quarter worth about $5,586,000. Finally, EAM Global Investors LLC purchased a new stake in shares of Oxford Immunotec Global in the first quarter worth about $1,330,000. Institutional investors and hedge funds own 91.18% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Article: NASDAQ
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.